Press release
Klebsiella pneumoniae Infections Market is expected to reach USD 7.21 billion by 2034
Klebsiella pneumoniae Infections
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71746
Klebsiella pneumoniae is a major cause of severe infections including pneumonia, bloodstream infections, urinary tract infections (UTIs), wound infections, and neonatal sepsis. The rise of multidrug-resistant (MDR) and carbapenem-resistant Klebsiella pneumoniae (CRKP) strains poses critical challenges to global health systems, driving strong demand for advanced antibiotics, combination therapies, rapid diagnostics, and infection-control solutions.
Biopharmaceutical companies and research institutes are increasingly focusing on developing next-generation antibacterial agents, β-lactam/β-lactamase inhibitor combinations, bacteriophages, monoclonal antibodies, and rapid point-of-care diagnostic tools to address escalating resistance patterns.
Key Market Highlights
• 2024 Market Size: USD 3.85 billion
• 2034 Forecast: USD 7.21 billion
• CAGR (2025-2034): 6.5%
• Largest Market: North America
• Fastest Growing Region: Asia Pacific
Market Drivers
1. Rising Antimicrobial Resistance (AMR)
The rapid spread of carbapenem-resistant and extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae strains is increasing the demand for advanced therapeutics and infection-control technologies.
2. Higher Hospitalization & ICU Admission Rates
Klebsiella is a leading cause of hospital-acquired infections, especially in intensive care units, neonatal wards, and surgical departments.
3. Growing Prevalence of Chronic Diseases
Diabetes, chronic obstructive pulmonary disease (COPD), renal failure, and immunosuppression increase patient susceptibility to severe infections.
4. Advancements in Rapid Diagnostics
Molecular diagnostic tests, PCR panels, MALDI-TOF systems, and AI-based bacterial identification tools are improving early detection and treatment accuracy.
5. Increased Investment in Bacteriophage and Novel Antibiotic R&D
Biotech and pharma companies are accelerating development of novel therapeutic approaches to combat MDR infections.
Market Restraints
• Limited effectiveness of traditional antibiotics against resistant strains
• High development costs for new antimicrobial agents
• Slow regulatory approvals for novel antibacterial therapies
• Inconsistent infection-control practices in low-resource healthcare settings
• Increased patient mortality associated with late diagnosis
Market Opportunities
1. Next-Generation Antibiotics & Novel Drug Combinations
β-lactam/β-lactamase inhibitor combinations, siderophore cephalosporins, and new carbapenem-sparing regimens offer strong commercial potential.
2. Rise of Bacteriophage Therapy & Immunotherapies
Phage-based treatments and monoclonal antibodies targeting Klebsiella virulence factors represent emerging, high-impact opportunities.
3. Rapid Point-of-Care Diagnostics
Decentralized diagnostic solutions allow early pathogen identification and targeted treatment.
4. Infection-Prevention Technologies
Hospital hygiene tools, antimicrobial surfaces, and ICU infection-control systems are gaining rapid adoption.
5. High Growth in Emerging Markets
Asia Pacific, Middle East, and Latin America are witnessing rapid increases in antimicrobial resistance and healthcare infrastructure expansion.
Segmentation Overview
By Treatment Type
• Antibiotics (carbapenems, cephalosporins, aminoglycosides, fluoroquinolones)
• β-lactam/β-lactamase inhibitor combinations
• Novel agents (siderophore cephalosporins, tetracycline derivatives)
• Bacteriophage therapy
• Supportive & symptomatic treatments
By Infection Type
• Pneumonia
• Bloodstream infections
• Urinary tract infections
• Wound & surgical site infections
• Neonatal sepsis
By End User
• Hospitals & ICUs
• Diagnostic laboratories
• Outpatient clinics
• Research institutions
Explore Full Report here: https://exactitudeconsultancy.com/reports/71746/klebsiella-pneumoniae-infections-market
Regional Insights
North America - Largest Market
High AMR surveillance, strong adoption of novel antibiotics, and advanced diagnostic infrastructure support regional dominance.
Europe - Strong Emphasis on Infection Control
National AMR action plans, strict antibiotic stewardship programs, and high diagnostic adoption fuel growth.
Asia Pacific - Fastest Growing Region
Drivers include high infection burden, rising hospital admissions, widespread antibiotic misuse, and improving healthcare infrastructure.
Latin America & Middle East/Africa - Emerging Potential
Increasing antimicrobial resistance rates and investments in modern hospital infrastructure drive demand.
Competitive Landscape
Key companies active in the Klebsiella pneumoniae infections market include:
• Pfizer
• Merck
• GlaxoSmithKline
• Johnson & Johnson
• Roche
• Novartis
• AbbVie
• Becton Dickinson
• Cipla
• Lupin
• Teva Pharmaceutical
• Shionogi
• Entasis Therapeutics
• Wockhardt
• Meiji Seika Pharma
These companies are investing in new antibacterial agents, rapid diagnostic systems, hospital infection-prevention tools, and genomic surveillance technologies.
Recent Market Developments
• Introduction of new β-lactam/β-lactamase inhibitor combinations targeting resistant Gram-negative infections
• Clinical trial progress for novel siderophore cephalosporins
• Expansion of bacteriophage therapy programs in clinical research centers
• AI-assisted diagnostic tools for rapid bacterial identification
• Strengthened global AMR surveillance and stewardship initiatives
Future Outlook (2025-2034)
The Klebsiella pneumoniae Infections Market is expected to evolve toward:
• Precision antimicrobial therapy guided by rapid diagnostics
• Reduced use of broad-spectrum antibiotics and increased adoption of targeted agents
• Growth in phage therapy and immunotherapeutic interventions
• Wider integration of AI in infection detection and hospital surveillance
Driven by rising antimicrobial resistance and expanding clinical awareness, the market will grow from USD 3.85 billion in 2024 to USD 7.21 billion by 2034, reflecting strong long-term demand for advanced infection-management solutions.
This report is also available in the following languages : Japanese (クレブシエラ肺炎感染症市場), Korean (클렙시엘라 폐렴균 감염 시장), Chinese (肺炎克雷伯菌感染市场), French (Marché des infections à Klebsiella pneumoniae), German (Markt für Klebsiella-pneumoniae-Infektionen), and Italian (Mercato delle infezioni da Klebsiella Pneumoniae), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71746
Our More Reports:
Coxsackievirus Infections Market
https://exactitudeconsultancy.com/reports/71960/coxsackievirus-infections-market
Eye Infections Market
https://exactitudeconsultancy.com/reports/71963/eye-infections-market
Catheter-related Bloodstream Infections Market
https://exactitudeconsultancy.com/reports/72875/catheter-related-bloodstream-infections-market
Skin Structure Infections Market
https://exactitudeconsultancy.com/reports/72883/skin-structure-infections-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Klebsiella pneumoniae Infections Market is expected to reach USD 7.21 billion by 2034 here
News-ID: 4306657 • Views: …
More Releases from Exactitude Consultancy
Cold Planer Market Sees Consistent Growth Supported by Global Road Rehabilitatio …
The global cold planer market is experiencing steady growth as governments and private contractors increase spending on road rehabilitation, resurfacing, and infrastructure modernization. Cold planers, also known as milling machines, are widely used to remove damaged asphalt and concrete surfaces efficiently, supporting sustainable road construction practices.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68250
Key Market Highlights
• Increasing focus on road maintenance and resurfacing projects
• Growing demand for efficient and precision milling…
Credit Management Software Market Accelerates as Organizations Focus on Risk Mit …
The global credit management software market is witnessing robust growth as organizations across industries adopt digital solutions to manage credit risk, improve receivables performance, and strengthen financial controls. Credit management software enables businesses to automate credit scoring, monitor customer creditworthiness, and streamline collections processes.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68248
Key Market Highlights
• Growing adoption of automated credit risk assessment tools
• Increasing focus on working capital and cash flow management
• Integration…
Session Border Controller Market Expands Rapidly as Enterprises and Telecom Oper …
The global session border controller (SBC) market is experiencing strong growth as telecom operators and enterprises increasingly deploy SBC solutions to secure, manage, and optimize real-time IP communications. SBCs play a critical role in protecting voice over IP (VoIP), unified communications (UC), and multimedia sessions from cyber threats while ensuring interoperability and quality of service.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68246
Key Market Highlights
• Growing adoption of VoIP and…
Biofuel Market Including E-Methane and Sustainable Aviation Fuel Gains Strong Tr …
The global biofuel market, encompassing e-methane, sustainable aviation fuel (SAF), and other advanced biofuels, is witnessing robust growth as governments and industries intensify efforts to reduce carbon emissions and transition toward cleaner energy sources. These fuels play a critical role in achieving net-zero targets while enabling decarbonization of hard-to-abate sectors such as aviation, shipping, and heavy transportation.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68244
Key Market Highlights
• Rapid growth of…
More Releases for Klebsiella
Klebsiella Pneumoniae Infections Market is projected to reach USD 5.0 billion by …
Klebsiella pneumoniae is a Gram-negative bacterium responsible for a wide range of healthcare- and community-acquired infections, including pneumonia, bloodstream infections, urinary tract infections (UTIs), and liver abscesses. It is a major concern in intensive care units (ICUs) and among immunocompromised patients.
The growing global burden of antimicrobial resistance (AMR) has made Klebsiella pneumoniae one of the most dangerous pathogens, particularly strains resistant to carbapenems, cephalosporins, and aminoglycosides. The World Health Organization…
Klebsiella Infections Therapeutics- Pipeline Analysis 2018, Clinical Trials & Re …
Klebsiella infections include different types of infections like bloodstream infections; pneumonia; wound or surgical site infections; and meningitis, caused by the Klebsiella bacteria. The symptoms associated with these infections are high fevers, chills, cough, and shortness of breath.
Download the sample report @ https://www.pharmaproff.com/request-sample/1065
Hospitalized patients undergoing treatment for other conditions may be susceptible to these infections. In healthcare settings, patients who require long courses of antibiotics, or are treated with…
Klebsiella Pneumoniae Infections Market Symptoms, Consulting Services, Epidemiol …
Klebsiella Pneumoniae Infections Market Epidemiology outlays comprehensive Insight of the disease, historical & forecasted epidemiology as well as the market trends of Klebsiella Pneumoniae Infections Industry. The Report provides a detailed picture of the current treatment practices, emerging drugs, a market share of the individual therapies, current and forecasted market size of Klebsiella Pneumoniae Infections.
The Klebsiella Pneumoniae Infections Market Report also covers current treatment practice/algorithm, market drivers, market barriers and…
Klebsiella pneumoniae Infections Market : Potential and Niche Segments, Geograph …
ReportBazzar has released its latest research-based report entitled ‘Klebsiella pneumoniae Infections’ market.
This report provides a holistic approach to the market growth with a detailed and precise analysis of the overall competitive scenario of the Klebsiella pneumoniae Infections market. The report also provides a detailed analysis of key trends and latest technologies, playing a prominent role in the Klebsiella pneumoniae Infections market growth. It takes into account aspects such as drivers,…
Klebsiella pneumoniae Infections (Infectious Disease) Pipeline Forecast Report, …
Market Research Hub's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2017, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape. Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic…
Global Therapeutic Landscape of Klebsiella pneumoniae Infections Pipeline Review …
Klebsiella pneumoniae Infections - Pipeline Review, H1 2017
Summary
Latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2017, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.
Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung…
